Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNS60 effects on biomarkers in amyotrophic lateral sclerosis
2016-002382-62Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in amyotrophic lateral sclerosis (ALS) comparing RNS60 plus riluzole with Placebo plus riluzole (2 arms). Primary endpoints: Change in regulatory T-cell proportion and Change in plasma biomarkers. Started Jun 2021; status: completed.
02
Drugs
RNS60
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2016-002382-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002382-62.